Reactions of alpha,beta -dehydrodipeptides containing a terminal gamma -aminobutyric acid residue with 3-ethoxycarbonylbenzotriazole I-oxide at 90-100 degreesC result mainly in cleavage of the peptide bond. In the cold, the corresponding ethyl ester and N-acyl-gamma -butyrolactam are formed. Analogous reactions with N-benzoyl- and N-benzyloxycarbonyl-gamma -aminobutyric acids leads to formation of the corresponding ethyl esters.
<i>Bacillus subtilis</i>Esterase (BS2) and its Double Mutant Have Different Selectivity in the Removal of Carboxyl Protecting Groups
作者:Efrosini Barbayianni、Christoforos G. Kokotos、Sebastian Bartsch、Christina Drakou、Uwe T. Bornscheuer、George Kokotos
DOI:10.1002/adsc.200900325
日期:2009.10
An esterase from Bacillus subtilis (BS2) and itsdoublemutant E188W/M193C quickly hydrolyze n-butyl, n-propyl, methoxyethyl and allyl esters. The wild-type BS2 preferentially removes such esters from the γ-position of glutamate diesters, while the engineered enzyme has a reversed selectivity removing esters from the α-position of glutamate diesters. Automated docking and molecular dynamic simulations
Enzymatic Removal of Carboxyl Protecting Groups. III. Fast Removal of Allyl and Chloroethyl Esters by <i>Bacillus subtilis</i> Esterase (BS2)
作者:Irene Fotakopoulou、Efrosini Barbayianni、Violetta Constantinou-Kokotou、Uwe T. Bornscheuer、George Kokotos
DOI:10.1021/jo061871f
日期:2007.2.1
esterase from Bacillus subtilis (BS2) allows the fast and selective removal of allyl, 2-chloroethyl, and 2,2,2-chloroethyl esters under mild conditions in high yields. In addition, BS2 easily hydrolyzes phenacyl esters, while the hydrolysis of sterically hindered diphenylmethyl esters is slow, requiring longer reaction time and higher enzyme/substrate ratio.
[EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
申请人:MIRATI THERAPEUTICS INC
公开号:WO2019217307A1
公开(公告)日:2019-11-14
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.